GSK acquires exclusive rights from Syndivia for antibody drug conjugate in prostate cancer
GSK Acquires Exclusive Rights for Antibody Drug Conjugate GSK plc and Syndivia, a private biotechnology company, have announced an agreement granting GSK exclusive worldwide rights to deve…